Aflibercept
|
|
|
- CAS-Nr.
- 845771-78-0
- Englisch Name:
- Aflibercept
- Synonyma:
- Zaltrap;Eylea;Aflibercep;AFLIBERCEPT;VEGF-trapR1;ziv-aflibercept;9: PN: US20050043236SEQID: 10 unclaiMed protein (9CI)
- CBNumber:
- CB21509108
- Summenformel:
- Molgewicht:
- 0
- MOL-Datei:
- Mol file
|
Aflibercept Eigenschaften
- Aggregatzustand
- Liquid
- Farbe
- Colorless to light yellow
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung
|
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitssch?dlich bei Verschlucken. |
Akute Toxizit?t oral |
Kategorie 4 |
Warnung |
|
P264, P270, P301+P312, P330, P501 |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
|
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
|
P264, P280, P305+P351+P338,P337+P313P |
| H335 |
Kann die Atemwege reizen. |
Spezifische Zielorgan-Toxizit?t (einmalige Exposition) |
Kategorie 3 (Atemwegsreizung) |
Warnung |
|
|
|
| Sicherheit |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen. |
|
Aflibercept Chemische Eigenschaften,Einsatz,Produktion Methoden
Mechanism of action
Aflibercept is a 115 kDa fusion protein. It consists of an IgG backbone fused to extracellular VEGF receptor sequences of the human VEGFR1 and VEGFR2. As a soluble decoy receptor, it binds VEGF-A with a greater affinity than its natural receptors. In an experimental model, aflibercept’s equilibrium disassociation constant (Kd, inversely related to binding affinity) for VEGF-A165 was 0.49 pM, compared with 9.33 pM and 88.8 pM for experimental native VEGFR1 and VEGFR2, respectively. Aflibercept’s high affinity for VEGF prevents the subsequent binding and activation of native VEGF receptors. Reduced VEGF activity leads to decreased angiogenesis and vascular permeability. Inhibition of PIGF and VEGF-B may also aid the treatment of angiogenic conditions. PIGF has been associated with angiogenesis and can be elevated in multiple conditions, such as wet AMD. VEGF-B overexpression has been connected with the breakdown of the blood-retinal barrier and retinal angiogenesis. Thus, inhibition of VEGF-A, VEGF-B, and PIGF may all contribute to the efficacy of aflibercept. Aflibercept has a unique binding action and binds to both sides of the VEGF dimer, forming an inert 1:1 complex called a VEGF trap. Additionally, aflibercept is the only drug in its class that binds to PIGF-2.
Aflibercept Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Aflibercept Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 76)Lieferanten
845771-78-0()Verwandte Suche:
- AFLIBERCEPT
- Eylea
- 9: PN: US20050043236SEQID: 10 unclaiMed protein (9CI)
- Aflibercep
- ziv-aflibercept
- VEGF-trapR1
- Zaltrap
- 845771-78-0
